BACKGROUND: There is evidence to suggest that antiretroviral therapy (ART) and testing for human immunodeficiency virus (HIV) reduce the probability of transmission of HIV. This has led health officials across the United States to take steps toward a test-and-treat policy. However, the extent of the benefits generated by test-and-treat is debatable, and there are concerns, such as increased multidrug resistance (MDR), that remain unaddressed. METHODS: We developed a deterministic epidemiologic model to simulate the HIV/AIDS epidemic for men who have sex with men (MSM) in Los Angeles County (LAC). We calibrated the model to match the HIV surveillance data from LAC across a 10-year period, starting in 2000. We then modified our model to simulate the test-and-treat policy and compared epidemiologic outcomes under the test-and-treat scenario to the status quo scenario over the years 2012-2023. Outcome measures included new infections, deaths, new AIDS cases, and MDR. RESULTS: Relative to the status quo, the test-and-treat model resulted in a 34% reduction in new infections, 19% reduction in deaths, and 39% reduction in new AIDS cases by 2023. However, these results are counterbalanced by a near doubling of the prevalence of MDR (9.06% compared to 4.79%) in 2023. We also found that the effects of increasing testing and treatment were not complementary. CONCLUSIONS: Although test-and-treat generates substantial benefits, it will not eliminate the epidemic for MSM in LAC. Moreover, these benefits are counterbalanced by large increases in MDR.
BACKGROUND: There is evidence to suggest that antiretroviral therapy (ART) and testing for human immunodeficiency virus (HIV) reduce the probability of transmission of HIV. This has led health officials across the United States to take steps toward a test-and-treat policy. However, the extent of the benefits generated by test-and-treat is debatable, and there are concerns, such as increased multidrug resistance (MDR), that remain unaddressed. METHODS: We developed a deterministic epidemiologic model to simulate the HIV/AIDS epidemic for men who have sex with men (MSM) in Los Angeles County (LAC). We calibrated the model to match the HIV surveillance data from LAC across a 10-year period, starting in 2000. We then modified our model to simulate the test-and-treat policy and compared epidemiologic outcomes under the test-and-treat scenario to the status quo scenario over the years 2012-2023. Outcome measures included new infections, deaths, new AIDS cases, and MDR. RESULTS: Relative to the status quo, the test-and-treat model resulted in a 34% reduction in new infections, 19% reduction in deaths, and 39% reduction in new AIDS cases by 2023. However, these results are counterbalanced by a near doubling of the prevalence of MDR (9.06% compared to 4.79%) in 2023. We also found that the effects of increasing testing and treatment were not complementary. CONCLUSIONS: Although test-and-treat generates substantial benefits, it will not eliminate the epidemic for MSM in LAC. Moreover, these benefits are counterbalanced by large increases in MDR.
Entities:
Keywords:
HIV/AIDS; antiretroviral therapy; drug resistance; mathematical model; test and treat
Authors: Wim Delva; David P Wilson; Laith Abu-Raddad; Marelize Gorgens; David Wilson; Timothy B Hallett; Alex Welte Journal: PLoS Med Date: 2012-07-10 Impact factor: 11.069
Authors: Jeffrey W Eaton; Leigh F Johnson; Joshua A Salomon; Till Bärnighausen; Eran Bendavid; Anna Bershteyn; David E Bloom; Valentina Cambiano; Christophe Fraser; Jan A C Hontelez; Salal Humair; Daniel J Klein; Elisa F Long; Andrew N Phillips; Carel Pretorius; John Stover; Edward A Wenger; Brian G Williams; Timothy B Hallett Journal: PLoS Med Date: 2012-07-10 Impact factor: 11.069
Authors: Seth C Kalichman; Devon Price; Lisa A Eaton; Kaylee Burnham; Matthew Sullivan; Stephanie Finneran; Talea Cornelius; Aerielle Allen Journal: Arch Sex Behav Date: 2017-02-06
Authors: Chris Beyrer; Stefan D Baral; Brian W Weir; James W Curran; Richard E Chaisson; Patrick S Sullivan Journal: Curr Opin HIV AIDS Date: 2014-03 Impact factor: 4.283
Authors: Dana P Goldman; Timothy Juday; Daniel Seekins; Mark T Linthicum; John A Romley Journal: Health Aff (Millwood) Date: 2014-03 Impact factor: 6.301
Authors: M-J Milloy; Evan Wood; Thomas Kerr; Bob Hogg; Silvia Guillemi; P Richard Harrigan; Julio Montaner Journal: Clin Infect Dis Date: 2015-11-08 Impact factor: 9.079